Svenskt biotechbolag nära genombrott i behandling mot covid-19 – söker investerare

Researchers at the biotech company Amniotics in Lund has developed a lung specific stem cell for treatment of covid-19. The market for treating lung- and airway diseases is valued at 47 billion Euro.

– At present, we are working day and night to finish our process validation. We are in close contact with the Swedish Medical Products Agency (Läkemedelsverket) to initiate a clinical trial and we hope to soon be able to send an application, says Kåre Engkilde, CEO at Amniotics.

In the News
16 April, 2020
WP to LinkedIn Auto Publish Powered By :